Hangzhou Zhongmei Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HANGZHOU ZHONGMEI, and what generic and branded alternatives to HANGZHOU ZHONGMEI drugs are available?
HANGZHOU ZHONGMEI has five approved drugs.
Summary for Hangzhou Zhongmei
| US Patents: | 0 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Hangzhou Zhongmei
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hangzhou Zhongmei | DAPTOMYCIN | daptomycin | POWDER;INTRAVENOUS | 215215-001 | Nov 26, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hangzhou Zhongmei | ACARBOSE | acarbose | TABLET;ORAL | 213821-002 | Aug 18, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Hangzhou Zhongmei | FONDAPARINUX SODIUM | fondaparinux sodium | INJECTABLE;SUBCUTANEOUS | 216493-004 | Aug 19, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hangzhou Zhongmei | TACROLIMUS | tacrolimus | CAPSULE;ORAL | 210929-002 | Apr 17, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
